1
|
Mazur G, Pańczyk-Straszak K, Rapacz A, Kiszela J, Smolik M, Gawlik M, Walczak M, Czekajewska J, Poloczek C, Karczewska E, Żesławska E, Nitek W, Niedbał A, Leśniak J, Ciapala K, Pawlik K, Mika J, Waszkielewicz AM. Promising anticonvulsant and/or analgesic compounds among 5-chloro-2- or 5-chloro-4-methyl derivatives of xanthone coupled to aminoalkanol moieties-Design, synthesis and pharmacological evaluation. Chem Biol Drug Des 2023; 101:278-325. [PMID: 35713377 DOI: 10.1111/cbdd.14102] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 05/26/2022] [Accepted: 06/12/2022] [Indexed: 01/14/2023]
Abstract
A series of 10 aminoalkanol derivatives of 5-chloro-2- or 5-chloro-4-methylxanthone was synthetized and evaluated for anticonvulsant properties (MES test, mice, intraperitoneal) and compared with neurotoxicity rotarod test (NT, mice, i.p.). The best results both in terms of anticonvulsant activity and protective index value were obtained for 3: 5-chloro-2-([4-hydroxypiperidin-1-yl]methyl)-9H-xanthen-9-one hydrochloride. Compounds: 1-3, 7 and 10 revealed ED50 values in MES test: 42.78, 31.64, 25.76, 46.19 and 52.50 mg/kg b.w., respectively. 3 showed 70% and 72% of inhibition control specific binding of sigma-1 (σ1) and sigma-2 (σ2) receptor, respectively. 3 exhibited also antinociceptive activity at dose 2 mg/kg b.w. after chronic constriction injury in mice. 1, 3, 7 and 10 were evaluated on gastrointestinal flora and proved safe. In genotoxicity test (UMU-Chromotest) compounds 1, 7 and 10 proved safe at dose 150-300 μg/ml. The pharmacokinetic analysis showed rapid absorption of all studied molecules from the digestive tract (tmax = 5-30 min). The bioavailability of the compounds ranged from 6.6% (1) to 16% (10). All studied compounds penetrate the blood-brain barrier with brain to plasma ratios varied from 4.15 (3) to 7.6 (compound 7), after i.v. administration, and from 1 (7) to 5.72 (3) after i.g. administration.
Collapse
Affiliation(s)
- Gabriela Mazur
- Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Katarzyna Pańczyk-Straszak
- Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Anna Rapacz
- Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Jan Kiszela
- Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Magdalena Smolik
- Chair and Department of Toxicology, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Maciej Gawlik
- Chair and Department of Toxicology, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Maria Walczak
- Chair and Department of Toxicology, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Joanna Czekajewska
- Department of Microbiology, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Celina Poloczek
- Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Elżbieta Karczewska
- Department of Microbiology, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Ewa Żesławska
- Institute of Biology, Pedagogical University of Krakow, Kraków, Poland
| | - Wojciech Nitek
- Department of Crystallochemistry and Crystallophysics, Faculty of Chemistry, Jagiellonian University, Kraków, Poland
| | - Anna Niedbał
- Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Joanna Leśniak
- Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - Katarzyna Ciapala
- Department of Pain Pharmacology, Maj Institute of Pharmacology, Kraków, Poland
| | - Katarzyna Pawlik
- Department of Pain Pharmacology, Maj Institute of Pharmacology, Kraków, Poland
| | - Joanna Mika
- Department of Pain Pharmacology, Maj Institute of Pharmacology, Kraków, Poland
| | - Anna M Waszkielewicz
- Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| |
Collapse
|
2
|
Waszkielewicz A, Marona H, Pańczyk-Straszak K, Filipek B, Rapacz A, Sałat K, Kubacka M, Cios A, Fedak F, Walczak M, Hubicka U, Kwiecień A, Żuromska-Witek B, Szafrański PW, Koczurkiewicz-Adamczyk P, Pękala E, Przejczowska-Pomierny K, Pociecha K, Wyska E. KM-408, a novel phenoxyalkyl derivative as a potential anticonvulsant and analgesic compound for the treatment of neuropathic pain. Pharmacol Rep 2023; 75:128-165. [PMID: 36401763 PMCID: PMC9889419 DOI: 10.1007/s43440-022-00431-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 10/21/2022] [Accepted: 10/25/2022] [Indexed: 11/21/2022]
Abstract
BACKGROUND Epilepsy frequently coexists with neuropathic pain. Our approach is based on the search for active compounds with multitarget profiles beneficial in terms of potential side effects and on the implementation of screening for potential multidirectional central activity. METHODS Compounds were synthesized by means of chemical synthesis. After antiseizure and neurotoxicity screening in vivo, KM-408 and its enantiomers were chosen for analgesic activity evaluations. Further safety studies included acute toxicity in mice, the effect on normal electrocardiogram and on blood pressure in rats, whole body plethysmography in rats, and in vitro and biochemical assays. Pharmacokinetics has been studied in rats after iv and po administration. Metabolism has been studied in vivo in rat serum and urine. Radioligand binding studies were performed as part of the mechanism of action investigation. RESULTS Selected results for KM-408: Ki sigma = 7.2*10-8; Ki 5-HT1A = 8.0*10-7; ED50 MES (mice, ip) = 13.3 mg/kg; formalin test (I phase, mice, ip)-active at 30 mg/kg; SNL (rats, ip)-active at 6 mg/kg; STZ-induced pain (mice, ip)-active at 1 mg/kg (von Frey) and 10 mg/kg (hot plate); hot plate test (mice, ip)-active at 30 mg/kg; ED50 capsaicin test (mice, ip) = 18.99 mg/kg; tail immersion test (mice)-active at 0.5%; corneal anesthesia (guinea pigs)-active at 0.125%; infiltration anesthesia (guinea pigs)-active at 0.125%. CONCLUSIONS Within the presented study a novel compound, R,S-2-((2-(2-chloro-6-methylphenoxy)ethyl)amino)butan-1-ol hydrochloride (KM-408) with dual antiseizure and analgesic activity has been developed for potential use in neuropathic pain treatment.
Collapse
Affiliation(s)
- Anna Waszkielewicz
- Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Henryk Marona
- Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Katarzyna Pańczyk-Straszak
- Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Barbara Filipek
- Department of Pharmacodynamics, Chair of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Anna Rapacz
- Department of Pharmacodynamics, Chair of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Kinga Sałat
- Department of Pharmacodynamics, Chair of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Monika Kubacka
- Department of Pharmacodynamics, Chair of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Agnieszka Cios
- Department of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Filip Fedak
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzyńskiego 14, 30-348 Kraków, Poland
| | - Maria Walczak
- Chair and Department of Toxicology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Urszula Hubicka
- Chair of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Anna Kwiecień
- Chair of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Barbara Żuromska-Witek
- Chair of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Przemysław W. Szafrański
- Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Paulina Koczurkiewicz-Adamczyk
- Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Elżbieta Pękala
- Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Katarzyna Przejczowska-Pomierny
- Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Krzysztof Pociecha
- Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Elżbieta Wyska
- Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| |
Collapse
|
3
|
Pańczyk‐Straszak K, Rapacz A, Marona H, Żelaszczyk D, Karczewska E, Zając M, Skiba‐Kurek I, Siwek A, Waszkielewicz A. Design, Synthesis and Anticonvulsant Activity of New Phenoxyalkyl, Phenoxyethoxyethyl and Phenoxyacetyl Derivatives of Aminoalkanols. ChemistrySelect 2022. [DOI: 10.1002/slct.202201233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Katarzyna Pańczyk‐Straszak
- Jagiellonian University Medical College Faculty of Pharmacy Chair of Organic Chemistry Department of Bioorganic Chemistry Medyczna 9 30-688 Kraków Poland
| | - Anna Rapacz
- Jagiellonian University Medical College Faculty of Pharmacy Department of Pharmacodynamics Medyczna 9 30-688 Kraków Poland
| | - Henryk Marona
- Jagiellonian University Medical College Faculty of Pharmacy Chair of Organic Chemistry Department of Bioorganic Chemistry Medyczna 9 30-688 Kraków Poland
| | - Dorota Żelaszczyk
- Jagiellonian University Medical College Faculty of Pharmacy Chair of Organic Chemistry Department of Bioorganic Chemistry Medyczna 9 30-688 Kraków Poland
| | - Elżbieta Karczewska
- Jagiellonian University Medical College Faculty of Pharmacy Department of Pharmaceutical Microbiology Medyczna 9 30-688 Kraków Poland
| | - Martyna Zając
- Jagiellonian University Medical College Faculty of Pharmacy Medyczna 9 30-688 Kraków Poland
| | - Iwona Skiba‐Kurek
- Jagiellonian University Medical College Faculty of Pharmacy Department of Pharmaceutical Microbiology Medyczna 9 30-688 Kraków Poland
| | - Agata Siwek
- Jagiellonian University Medical College Faculty of Pharmacy Department of Pharmacobiology Medyczna 9 30-688 Kraków Poland
| | - Anna Waszkielewicz
- Jagiellonian University Medical College Faculty of Pharmacy Chair of Organic Chemistry Department of Bioorganic Chemistry Medyczna 9 30-688 Kraków Poland
| |
Collapse
|